Pre-Market Analysis: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc.

 Pre-Market Analysis: Dendreon Corp., Stryker Corp., Novartis AG, and Repros
                              Therapeutics Inc.

PR Newswire

LONDON, August 20, 2013

LONDON, August 20, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.



The US equity market closed on a lower note on Monday, August 19, 2013. All
three benchmark indexes declined, with the Dow Jones Industrial Average
falling 0.47%, the S&P 500 falling 0.59%, and the NASDAQ composite declining
0.38%. Shares in the healthcare industry ended on a mixed note, even as the
broader market declined. The major movers in the sector included Dendreon
Corporation (NASDAQ: DNDN), Stryker Corporation (NYSE: SYK), Novartis AG
(NYSE: NVS), and Repros Therapeutics Inc. (NASDAQ: RPRX). All these companies
are tracked by AAAResearchReports.com. Free technical research on DNDN, SYK,
NVS, and RPRX can be downloaded upon signing up at:

http://www.aaaresearchreports.com/register/ 

Shares in Dendreon Corporation ended the day 0.94% lower at $3.15 after
fluctuating between $3.13 and $3.28. A total of 3.58 million shares were
traded, which is below the daily average volume of 4.09 million. The company's
shares have lost 0.94% in the last three trading sessions, outperforming the
S&P 500 which has lost 2.33% during the same period. Moreover, the stock is
currently trading below its 50-day and 200-day moving averages. Sign up and
read the complimentary report on DNDN at:

http://www.AAAResearchReports.com/DNDN082013.pdf

Stryker Corporation's stock ended slightly higher on Monday, finishing at
$68.06, up 0.13% from its previous closing price. The company's shares
fluctuated between $67.82 and $68.54. A total of 0.83 million shares were
traded, which is below the daily average volume of 1.27 million. The company's
shares have lost 1.22% in last three months, outperforming the S&P 500 which
has lost 1.28% during the same period. The free report on SYK can be
downloaded by signing up now at:

http://www.AAAResearchReports.com/SYK082013.pdf

Shares in Novartis AG posted modest gains on Monday. The company's shares
traded between $72.81 and $73.21 before finishing the day 0.08% higher at
$72.90. A total of 1.53 million shares were traded, which is above the daily
average volume of 1.43 million. The company's shares have gained 0.45% in the
last one month, compared to a loss of 2.72% in the S&P 500 during the same
period. Furthermore, the stock is currently trading above its 50-day and
200-day moving averages. A free report on NVS can be accessed by registering
at:

http://www.AAAResearchReports.com/NVS082013.pdf

Shares in Repros Therapeutics Inc. fell sharply on Monday as the broader
market finished on a lower note. The company's shares ended the session 2.16%
lower at $19.01 after oscillating between $18.90 and $19.97. A total of 0.52
million shares were traded, which is above the daily average volume of 0.43
million. The company's shares have gained 1.93% in the last three trading
sessions, and 13.90% in the last three months, outperforming the S&P 500 which
has lost 2.33% and 1.28%, during the respective periods. Moreover, the stock
is currently trading above its 200-day moving average. Register with AAA
Research Reports and download research on RPRX for free at:

http://www.AAAResearchReports.com/RPRX082013.pdf

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA ® charterholder. However, we are only human
    and are prone to make mistakes. If you notice any errors or omissions,
    please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://www.AAAresearchreports.com

SOURCE AAA Research Reports

Contact: Peter F. Jones; Phone #: + 1 (646) 396-9126, Email ID:
info@aaaresearchreports.com